Summary
Global Markets Direct’s, ‘Peritoneal Cancer - Pipeline Review, H1 2016’, provides an overview of the Peritoneal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Adaptimmune Therapeutics Plc
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advenchen Laboratories, LLC
Amgen Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
AVEO Pharmaceuticals, Inc.
Bayer AG
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Caladrius Biosciences, Inc.
Celldex Therapeutics, Inc.
Celsion Corporation
CerRx, Inc.
Cerulean Pharma, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Critical Outcome Technologies Inc.
CritiTech, Inc.
CTI BioPharma Corp.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Ganymed Pharmaceuticals AG
Genelux Corporation
Genentech, Inc.
Genor BioPharma Co., Ltd.
Glycotope GmbH
Gradalis Inc.
Hemispherx Biopharma, Inc.
ImmunoGen, Inc.
Immunovaccine, Inc.
Incyte Corporation
Innate Pharma S.A.
Johnson & Johnson
Juno Therapeutics Inc.
Kyowa Hakko Kirin Co., Ltd.
Lee's Pharmaceutical Holdings Limited
Mabion SA
MabVax Therapeutics Holdings, Inc.
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Mycenax Biotech Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolix, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Oxford BioMedica Plc
OXiGENE, Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
PsiOxus Therapeutics Limited
Quest PharmaTech Inc.
Sanofi Pasteur SA
Shenzen SiBiono GeneTech Co., Ltd.
Sotio a.s.
Synta Pharmaceuticals Corp.
TapImmune Inc.
Tesaro, Inc.
TetraLogic Pharmaceuticals
Tyrogenex, Inc.
Vascular Biogenics Ltd.
VentiRx Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Peritoneal Cancer Overview 12
Therapeutics Development 13
Pipeline Products for Peritoneal Cancer - Overview 13
Pipeline Products for Peritoneal Cancer - Comparative Analysis 14
Peritoneal Cancer - Therapeutics under Development by Companies 15
Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 21
Peritoneal Cancer - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Peritoneal Cancer - Products under Development by Companies 25
Peritoneal Cancer - Products under Investigation by Universities/Institutes 32
Peritoneal Cancer - Companies Involved in Therapeutics Development 33
AbbVie Inc. 33
Acetylon Pharmaceuticals, Inc. 34
Adaptimmune Therapeutics Plc 35
Aduro BioTech, Inc. 36
Advanced Accelerator Applications SA 37
Advenchen Laboratories, LLC 38
Amgen Inc. 39
Array BioPharma Inc. 40
Astex Pharmaceuticals, Inc. 41
AstraZeneca Plc 42
Atara Biotherapeutics, Inc. 43
AVEO Pharmaceuticals, Inc. 44
Bayer AG 45
Boehringer Ingelheim GmbH 46
Boston Biomedical, Inc. 47
Caladrius Biosciences, Inc. 48
Celldex Therapeutics, Inc. 49
Celsion Corporation 50
CerRx, Inc. 51
Cerulean Pharma, Inc. 52
Clovis Oncology, Inc. 53
Corcept Therapeutics Incorporated 54
Critical Outcome Technologies Inc. 55
CritiTech, Inc. 56
CTI BioPharma Corp. 57
Dr. Reddy's Laboratories Limited 58
EirGenix Inc. 59
Eli Lilly and Company 60
Epirus Biopharmaceuticals, Inc. 61
Exelixis, Inc. 62
F. Hoffmann-La Roche Ltd. 63
Galena Biopharma, Inc. 64
Ganymed Pharmaceuticals AG 65
Genelux Corporation 66
Genentech, Inc. 67
Genor BioPharma Co., Ltd. 68
Glycotope GmbH 69
Gradalis Inc. 70
Hemispherx Biopharma, Inc. 71
ImmunoGen, Inc. 72
Immunovaccine, Inc. 73
Incyte Corporation 74
Innate Pharma S.A. 75
Johnson & Johnson 76
Juno Therapeutics Inc. 77
Kyowa Hakko Kirin Co., Ltd. 78
Lee's Pharmaceutical Holdings Limited 79
Mabion SA 80
MabVax Therapeutics Holdings, Inc. 81
MedImmune, LLC 82
Medivation, Inc. 83
Merck & Co., Inc. 84
Millennium Pharmaceuticals, Inc. 85
MolMed S.p.A. 86
Mycenax Biotech Inc. 87
Novartis AG 88
Oasmia Pharmaceutical AB 89
OBI Pharma, Inc. 90
Oncobiologics, Inc. 91
Oncolix, Inc. 92
Oncolytics Biotech Inc. 93
OncoMed Pharmaceuticals, Inc. 94
Ono Pharmaceutical Co., Ltd. 95
Oxford BioMedica Plc 96
OXiGENE, Inc. 97
Pharma Mar, S.A. 98
Pharmacyclics, Inc. 99
PsiOxus Therapeutics Limited 100
Quest PharmaTech Inc. 101
Sanofi Pasteur SA 102
Shenzen SiBiono GeneTech Co., Ltd. 103
Sotio a.s. 104
Synta Pharmaceuticals Corp. 105
TapImmune Inc. 106
Tesaro, Inc. 107
TetraLogic Pharmaceuticals 108
Tyrogenex, Inc. 109
Vascular Biogenics Ltd. 110
VentiRx Pharmaceuticals, Inc. 111
Peritoneal Cancer - Therapeutics Assessment 112
Assessment by Monotherapy Products 112
Assessment by Target 113
Assessment by Mechanism of Action 120
Assessment by Route of Administration 125
Assessment by Molecule Type 127
Drug Profiles 129
²¹²Pb-TCMC-Trastuzumab - Drug Profile 129
abexinostat hydrochloride - Drug Profile 131
abiraterone acetate - Drug Profile 134
ABT-767 - Drug Profile 137
acalabrutinib - Drug Profile 138
adagloxad simolenin - Drug Profile 141
afuresertib hydrochloride - Drug Profile 143
AL-3818 - Drug Profile 146
alisertib - Drug Profile 148
anetumab ravtansine - Drug Profile 153
AV-203 - Drug Profile 155
AZD-1775 - Drug Profile 157
AZD-2014 - Drug Profile 159
AZD-5363 - Drug Profile 162
BB-503 - Drug Profile 164
bevacizumab - Drug Profile 166
bevacizumab biosimilar - Drug Profile 173
bevacizumab biosimilar - Drug Profile 175
bevacizumab biosimilar - Drug Profile 176
bevacizumab biosimilar - Drug Profile 177
bevacizumab biosimilar - Drug Profile 178
bevacizumab biosimilar - Drug Profile 179
bevacizumab biosimilar - Drug Profile 180
bevacizumab biosimilar - Drug Profile 181
binimetinib - Drug Profile 182
birinapant - Drug Profile 187
cabozantinib s-malate - Drug Profile 190
catumaxomab - Drug Profile 195
CDX-1401 - Drug Profile 198
Cellular Immunotherapy for Oncology - Drug Profile 200
Cellular Immunotherapy for Oncology - Drug Profile 202
Cellular Immunotherapy for Oncology - Drug Profile 203
Cellular Immunotherapy for Ovarian, Peritoneal and Fallopian Tube Cancer - Drug Profile 204
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile 205
COTI-2 - Drug Profile 207
CRLX-101 - Drug Profile 210
CRS-207 - Drug Profile 213
DCVAC/OvCa - Drug Profile 216
demcizumab - Drug Profile 217
DMUC-4064A - Drug Profile 221
DPX-Survivac - Drug Profile 222
eltrapuldencel-T - Drug Profile 226
enadenotucirev - Drug Profile 229
epacadostat - Drug Profile 231
fenretinide - Drug Profile 233
fosbretabulin tromethamine - Drug Profile 235
GALE-301 - Drug Profile 239
ganetespib - Drug Profile 241
gemogenovatucel-T - Drug Profile 246
GEN-1 - Drug Profile 248
Gene Therapy to Activate p53 for Oncology - Drug Profile 251
gimatecan - Drug Profile 252
GLONC-1 - Drug Profile 254
GLV-1h153 - Drug Profile 257
GSK-3377794 - Drug Profile 258
guadecitabine - Drug Profile 261
IMAB-027 - Drug Profile 265
ipafricept - Drug Profile 266
JCAR-020 - Drug Profile 268
LCL-161 - Drug Profile 269
lifastuzumab vedotin - Drug Profile 271
lurbinectedin - Drug Profile 273
MesoCART - Drug Profile 277
mifepristone - Drug Profile 278
mirvetuximab soravtansine - Drug Profile 281
MK-2206 - Drug Profile 283
monalizumab - Drug Profile 286
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 288
motolimod - Drug Profile 289
MV-NIS - Drug Profile 291
NGR-hTNF - Drug Profile 293
nintedanib - Drug Profile 297
niraparib - Drug Profile 303
nivolumab - Drug Profile 306
NSC-748933 - Drug Profile 314
ofranergene obadenovec - Drug Profile 316
Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile 318
oregovomab - Drug Profile 320
OXB-301 - Drug Profile 322
paclitaxel - Drug Profile 325
paclitaxel - Drug Profile 328
paclitaxel poliglumex - Drug Profile 330
PankoMab-GEX - Drug Profile 334
pazopanib hydrochloride - Drug Profile 335
pelareorep - Drug Profile 341
pembrolizumab - Drug Profile 346
prexasertib - Drug Profile 357
Prolanta - Drug Profile 359
ralimetinib mesylate - Drug Profile 361
ramucirumab - Drug Profile 363
regorafenib - Drug Profile 369
ricolinostat - Drug Profile 373
rintatolimod - Drug Profile 376
rucaparib phosphate - Drug Profile 378
selumetinib sulfate - Drug Profile 381
sonidegib phosphate - Drug Profile 385
STM-434 - Drug Profile 389
talazoparib - Drug Profile 390
Theranean - Drug Profile 393
tivozanib hydrochloride - Drug Profile 394
TPIV-200 - Drug Profile 398
trabectedin - Drug Profile 400
trebananib - Drug Profile 406
tremelimumab - Drug Profile 409
Vaccine for Oncology - Drug Profile 412
VCP-2292 - Drug Profile 413
veliparib - Drug Profile 414
X-82 - Drug Profile 418
Peritoneal Cancer - Recent Pipeline Updates 420
Peritoneal Cancer - Dormant Projects 672
Peritoneal Cancer - Discontinued Products 676
Peritoneal Cancer - Product Development Milestones 677
Featured News & Press Releases 677
Appendix 683
Methodology 683
Coverage 683
Secondary Research 683
Primary Research 683
Expert Panel Validation 683
Contact Us 683
Disclaimer 684
List of Tables
Number of Products under Development for Peritoneal Cancer, H1 2016 20
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2016 21
Number of Products under Development by Companies, H1 2016 22
Number of Products under Development by Companies, H1 2016 (Contd..1) 23
Number of Products under Development by Companies, H1 2016 (Contd..2) 24
Number of Products under Development by Companies, H1 2016 (Contd..3) 25
Number of Products under Development by Companies, H1 2016 (Contd..4) 26
Number of Products under Development by Companies, H1 2016 (Contd..5) 27
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Development, H1 2016 31
Products under Development by Companies, H1 2016 32
Products under Development by Companies, H1 2016 (Contd..1) 33
Products under Development by Companies, H1 2016 (Contd..2) 34
Products under Development by Companies, H1 2016 (Contd..3) 35
Products under Development by Companies, H1 2016 (Contd..4) 36
Products under Development by Companies, H1 2016 (Contd..5) 37
Products under Development by Companies, H1 2016 (Contd..6) 38
Products under Investigation by Universities/Institutes, H1 2016 39
Peritoneal Cancer - Pipeline by AbbVie Inc., H1 2016 40
Peritoneal Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 41
Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 42
Peritoneal Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 43
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2016 44
Peritoneal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 45
Peritoneal Cancer - Pipeline by Amgen Inc., H1 2016 46
Peritoneal Cancer - Pipeline by Array BioPharma Inc., H1 2016 47
Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 48
Peritoneal Cancer - Pipeline by AstraZeneca Plc, H1 2016 49
Peritoneal Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 50
Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 51
Peritoneal Cancer - Pipeline by Bayer AG, H1 2016 52
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 53
Peritoneal Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 54
Peritoneal Cancer - Pipeline by Caladrius Biosciences, Inc. , H1 2016 55
Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 56
Peritoneal Cancer - Pipeline by Celsion Corporation, H1 2016 57
Peritoneal Cancer - Pipeline by CerRx, Inc., H1 2016 58
Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 59
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 60
Peritoneal Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016 61
Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 62
Peritoneal Cancer - Pipeline by CritiTech, Inc., H1 2016 63
Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H1 2016 64
Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 65
Peritoneal Cancer - Pipeline by EirGenix Inc., H1 2016 66
Peritoneal Cancer - Pipeline by Eli Lilly and Company, H1 2016 67
Peritoneal Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 68
Peritoneal Cancer - Pipeline by Exelixis, Inc., H1 2016 69
Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 70
Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H1 2016 71
Peritoneal Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2016 72
Peritoneal Cancer - Pipeline by Genelux Corporation, H1 2016 73
Peritoneal Cancer - Pipeline by Genentech, Inc., H1 2016 74
Peritoneal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 75
Peritoneal Cancer - Pipeline by Glycotope GmbH, H1 2016 76
Peritoneal Cancer - Pipeline by Gradalis Inc., H1 2016 77
Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2016 78
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H1 2016 79
Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H1 2016 80
Peritoneal Cancer - Pipeline by Incyte Corporation, H1 2016 81
Peritoneal Cancer - Pipeline by Innate Pharma S.A., H1 2016 82
Peritoneal Cancer - Pipeline by Johnson & Johnson, H1 2016 83
Peritoneal Cancer - Pipeline by Juno Therapeutics Inc., H1 2016 84
Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 85
Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 86
Peritoneal Cancer - Pipeline by Mabion SA, H1 2016 87
Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 88
Peritoneal Cancer - Pipeline by MedImmune, LLC, H1 2016 89
Peritoneal Cancer - Pipeline by Medivation, Inc., H1 2016 90
Peritoneal Cancer - Pipeline by Merck & Co., Inc., H1 2016 91
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 92
Peritoneal Cancer - Pipeline by MolMed S.p.A., H1 2016 93
Peritoneal Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 94
Peritoneal Cancer - Pipeline by Novartis AG, H1 2016 95
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016 96
Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H1 2016 97
Peritoneal Cancer - Pipeline by Oncobiologics, Inc., H1 2016 98
Peritoneal Cancer - Pipeline by Oncolix, Inc., H1 2016 99
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 100
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 101
Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 102
Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H1 2016 103
Peritoneal Cancer - Pipeline by OXiGENE, Inc., H1 2016 104
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H1 2016 105
Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 106
Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 107
Peritoneal Cancer - Pipeline by Quest PharmaTech Inc., H1 2016 108
Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H1 2016 109
Peritoneal Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 110
Peritoneal Cancer - Pipeline by Sotio a.s., H1 2016 111
Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 112
Peritoneal Cancer - Pipeline by TapImmune Inc., H1 2016 113
Peritoneal Cancer - Pipeline by Tesaro, Inc., H1 2016 114
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016 115
Peritoneal Cancer - Pipeline by Tyrogenex, Inc., H1 2016 116
Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd., H1 2016 117
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 118
Assessment by Monotherapy Products, H1 2016 119
Number of Products by Stage and Target, H1 2016 121
Number of Products by Stage and Mechanism of Action, H1 2016 128
Number of Products by Stage and Route of Administration, H1 2016 133
Number of Products by Stage and Molecule Type, H1 2016 135
Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 427
Peritoneal Cancer - Dormant Projects, H1 2016 679
Peritoneal Cancer - Dormant Projects (Contd..1), H1 2016 680
Peritoneal Cancer - Dormant Projects (Contd..2), H1 2016 681
Peritoneal Cancer - Dormant Projects (Contd..3), H1 2016 682
Peritoneal Cancer - Discontinued Products, H1 2016 683
List of Figures
Number of Products under Development for Peritoneal Cancer, H1 2016 20
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2016 21
Number of Products under Development by Companies, H1 2016 22
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Products, H1 2016 31
Assessment by Monotherapy Products, H1 2016 119
Number of Products by Top 10 Targets, H1 2016 120
Number of Products by Stage and Top 10 Targets, H1 2016 120
Number of Products by Top 10 Mechanism of Actions, H1 2016 127
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 127
Number of Products by Top 10 Routes of Administration, H1 2016 132
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 132
Number of Products by Top 10 Molecule Types, H1 2016 134
Number of Products by Stage and Top 10 Molecule Types, H1 2016 134
